Artelo Biosciences Inc
ARTL6.790USD
+0.220+3.21%
Cierre 06/27, 16:00（ET）Cotizaciones retrasadas 15 min
22.28MCap. mercado
PérdidaP/E TTM
Más Datos de Artelo Biosciences Inc Compañía
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Información de la empresa
Símbolo de cotizaciónARTL
Nombre de la empresaArtelo Biosciences Inc
Fecha de salida a bolsaOct 13, 2015
Fundada en2011
Director ejecutivoMr. Gregory D. (Greg) Gorgas
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 13
Dirección505 Lomas Santa Fe, Suite 160
CiudadSOLANA BEACH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92075
Teléfono18589257049
Sitio Webhttps://artelobio.com/
Símbolo de cotizaciónARTL
Fecha de salida a bolsaOct 13, 2015
Fundada en2011
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Geode Capital Management, L.L.C.
0.82%
Citadel Advisors LLC
0.69%
Gorgas (Gregory D)
0.62%
Susquehanna International Group, LLP
0.62%
UBS Financial Services, Inc.
0.39%
Other
96.86%
Accionistas
Accionistas
Proporción
Geode Capital Management, L.L.C.
0.82%
Citadel Advisors LLC
0.69%
Gorgas (Gregory D)
0.62%
Susquehanna International Group, LLP
0.62%
UBS Financial Services, Inc.
0.39%
Other
96.86%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
1.01%
Investment Advisor/Hedge Fund
0.90%
Individual Investor
0.81%
Hedge Fund
0.81%
Other
96.47%
Participación institucional
Actualizado: lun., 3 de mar
Actualizado: lun., 3 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
23
63.92K
1.95%
-37.27K
2024Q4
25
63.92K
1.95%
-99.86K
2024Q3
26
51.99K
1.61%
-115.04K
2024Q2
32
55.13K
1.71%
-137.29K
2024Q1
31
54.26K
1.68%
-150.15K
2023Q4
38
55.07K
1.83%
-168.01K
2023Q3
40
80.20K
2.79%
-263.28K
2023Q2
40
67.48K
2.36%
-288.11K
2023Q1
40
75.80K
2.65%
-285.67K
2022Q4
41
142.96K
5.02%
-236.79K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Geode Capital Management, L.L.C.
17.35K
0.53%
--
--
Dec 31, 2024
Gorgas (Gregory D)
20.45K
0.62%
--
--
Feb 27, 2025
UBS Financial Services, Inc.
13.30K
0.41%
+13.30K
--
Dec 31, 2024
Tower Research Capital LLC
3.82K
0.12%
-1.36K
-26.34%
Dec 31, 2024
Matsui (Connie L)
3.78K
0.12%
--
--
Feb 27, 2025
Northern Trust Investments, Inc.
2.68K
0.08%
+2.68K
--
Dec 31, 2023
Blayney (Douglas W)
834.00
0.03%
--
--
Feb 27, 2025
Kelly (Steven)
834.00
0.03%
--
--
Feb 27, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Fecha
Tipo
Relación
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
